SARS-CoV-2 Antibodies; serum

Order: SAMPLE REPORT
Client #: 12345
Doctor: Sample Doctor
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174

Patient: Sample Patient
Age: 35
Sex: Female

Sample Collection	Date/Time
Date Collected	06/12/2020
Date Received	06/13/2020
Date Reported	06/14/2020

Analyte	Result	Reference Interval
SARS-CoV-2 IgG Antibody	Positive	Negative

Information

- Positive results suggest recent or prior infection with SARS-CoV-2. Results from antibody testing should not be used as the sole basis to diagnose or exclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary. False positive results may occur due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
- This assay was performed using the Beckman Coulter SARS-CoV-2 Antibody Assay. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Notes:
Methodology: Enzyme Immunoassay

Analyzed by DOCTOR'S DATA, INC. • 3755 Illinois Avenue, St. Charles, IL 60174-2420 USA • LAB DIR: Erlo Roth, MD • CLIA ID: 14D0646470

SARS-CoV-2 Antibodies; serum

Order: SAMPLE REPORT
Client #: 12345
Doctor: Sample Doctor
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174

Patient: Sample Patient
Age: 35
Sex: Female

Sample Collection	Date/Time
Date Collected	06/12/2020
Date Received	06/13/2020
Date Reported	06/14/2020

Analyte	Result	Reference Interval
SARS-CoV-2 IgG Antibody	Negative	Negative

Information

- This sample does not contain detectable SARS-CoV-2 IgG antibodies. Negative results do not preclude acute SARS-CoV-2 infection. Results from antibody testing should not be used as the sole basis to diagnose or exclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
- This assay was performed using the Beckman Coulter SARS-CoV-2 Antibody Assay. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Notes:
Methodology: Enzyme Immunoassay

Analyzed by DOCTOR'S DATA, INC. • 3755 Illinois Avenue, St. Charles, IL 60174-2420 USA • LAB DIR: Erlo Roth, MD • CLIA ID: 14D0646470

SARS-CoV-2 Antibodies; serum

Order: SAMPLE REPORT
Client #: 12345
Doctor: Sample Doctor
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174

Patient: Sample Patient
Age: 35
Sex: Female

Sample Collection	Date/Time
Date Collected	06/12/2020
Date Received	06/13/2020
Date Reported	06/14/2020

Analyte	Result	Reference Interval
SARS-CoV-2 IgG Antibody	Equivocal	Negative

Information

- Equivocal results may be consistent with early development of antibodies or declining levels of antibodies after infection with SARS-CoV-2. Repeat testing at a later date is recommended. Results from antibody testing should not be used as the sole basis to diagnose or exclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary. False positive results may occur due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
- This assay was performed using the Beckman Coulter SARS-CoV-2 Antibody Assay. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Notes:
Methodology: Enzyme Immunoassay

Analyzed by DOCTOR'S DATA, INC. • 3755 Illinois Avenue, St. Charles, IL 60174-2420 USA • LAB DIR: Erlo Roth, MD • CLIA ID: 14D0646470